Injection burden and treatment intervals of aflibercept in observe-and-plan regimen for neovascular age-related macular degeneration.
aflibercept
neovascular age‐related macular degeneration
observe‐and‐plan
real‐world data
treatment regimen
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
11 May 2024
11 May 2024
Historique:
received:
29
01
2024
accepted:
30
04
2024
medline:
11
5
2024
pubmed:
11
5
2024
entrez:
11
5
2024
Statut:
aheadofprint
Résumé
The Observe-and-Plan (O&P) regimen allows for individualised treatment. In this study, we evaluated injection burden and intervals using aflibercept in an O&P regimen for eyes with neovascular age-related macular degeneration (AMD). This was a retrospective registry-based study of treatment-naïve eyes with neovascular AMD. Treatment data were compiled for 3 years after commencement of intravitreal aflibercept therapy. We evaluated clinical consequences at the first follow-up after loading dose, the proportion of patients who obtained and kept dry macula after loading dose, number of injections and intervals between injections. Data were obtained for 1103 eyes. After loading dose, 0.4% were lost to follow-up, 7.5% discontinued, 50.9% booked for further injections and 41.3% booked for monthly observations. After loading dose, the macula remained dry in 49.2% at 3 months, 34.0% at 6 months, 23.7% at 12 months and 15.2% at 24 months. For the entire population, median cumulative total number of injections was 7, 12 and 15, after 1, 2 and 3 years, respectively. After the 3rd year, the proportion of eyes in the short 4-6 weeks treatment interval was 51.1%, 8 weeks interval was kept in 14.4% and the extended treatment intervals of 10 and 12 weeks was possible in 34.4%. After loading dose, one in two eyes required further injections. A large proportion required therapy with shorter intervals than the label-recommended 8 weeks. The large majority of those who obtained a dry macula after loading dose turned exudative again, mostly within the first 3 months.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Barequet, D., Shor, R., Segal, O., Greenbaum, E., Trivizki, O., Loewenstein, A. et al. (2023) Treatment patterns and visual acuity change of AMD patients, before, during and after the COVID‐19 pandemic lockdowns: a large cohort. Acta Ophthalmologica, 102, e322–e327. Available from: https://doi.org/10.1111/aos.15756
Bloch, S.B., Larsen, M. & Munch, I.C. (2012) Incidence of legal blindness from age‐related macular degeneration in Denmark: year 2000 to 2010. American Journal of Ophthalmology, 153, 209–213.e2.
Borrelli, E., Battista, M., Vella, G., Grosso, D., Sacconi, R., Querques, L. et al. (2021) The COVID‐19 pandemic has had negative effects on baseline clinical presentation and outcomes of patients with newly diagnosed treatment‐Naïve exudative AMD. Journal of Clinical Medicine, 10, 1265.
Brown, D.M., Kaiser, P.K., Michels, M., Soubrane, G., Heier, J.S., Kim, R.Y. et al. (2006) Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. The New England Journal of Medicine, 355, 1432–1444. Available from: https://doi.org/10.1056/NEJMoa062655
Cohen, S.Y., Dubois, L., Nghiem‐Buffet, S., Ayrault, S., Fajnkuchen, F., Guiberteau, B. et al. (2010) Retinal pseudocysts in age‐related geographic atrophy. American Journal of Ophthalmology, 150, 211–217.e1.
Colijn, J.M., Buitendijk, G.H.S., Prokofyeva, E., Alves, D., Cachulo, M.L., Khawaja, A.P. et al. (2017) Prevalence of age‐related macular degeneration in Europe: the past and the future. Ophthalmology, 124, 1753–1763.
Colijn, J.M., Meester‐Smoor, M., Verzijden, T., de Breuk, A., Silva, R., Merle, B.M.J. et al. (2021) Genetic risk, lifestyle, and age‐related macular degeneration in Europe: the EYE‐RISK consortium. Ophthalmology, 128, 1039–1049.
Danish Ophthalmological Society (2017): https://dansk‐oftalmologisk‐selskab.dk/wp‐content/uploads/2021/05/Aldersrelateret‐maculadegeneration‐AMD.pdf. Accessed December 27, 2023.
Freund, K.B., Korobelnik, J.F., Devenyi, R., Framme, C., Galic, J., Herbert, E. et al. (2015) TREAT‐AND‐EXTEND REGIMENS WITH ANTI‐VEGF AGENTS IN RETINAL DISEASES: a literature review and consensus recommendations. Retina, 35, 1489–1506.
Haji, H., Gianniou, C., Brynskov, T., Sørensen, T.L., Olsen, R. & Krogh Nielsen, M. (2023) Association between structural and functional treatment outcomes in neovascular age‐related macular degeneration. Acta Ophthalmologica, 101, 177–184.
Jeong, S., Ryu, G. & Sagong, M. (2021) Modified observe‐and‐plan regimen using aflibercept for neovascular age‐related macular degeneration. Acta Ophthalmologica, 99, e1535–e1536.
Khanna, S., Komati, R., Eichenbaum, D.A., Hariprasad, I., Ciulla, T.A. & Hariprasad, S.M. (2019) Current and upcoming anti‐VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmology, 4, e000398.
Mantel, I., Niderprim, S.A., Gianniou, C., Deli, A. & Ambresin, A. (2014) Reducing the clinical burden of ranibizumab treatment for neovascular age‐related macular degeneration using an individually planned regimen. The British Journal of Ophthalmology, 98, 1192–1196.
Matonti, F., Korobelnik, J.F., Dot, C., Gualino, V., Soler, V., Mrejen, S. et al. (2022) Comparative effectiveness of intravitreal anti‐vascular endothelial growth factor therapies for managing neovascular age‐related macular degeneration: a meta‐analysis. Journal of Clinical Medicine, 11, 1834.
Nielsen, M.K., Subhi, Y., Molbech, C.R., Grønskov, K. & Sørensen, T.L. (2020) Distribution of risk alleles in patients with age‐related macular degeneration. Danish Medical Journal, 67, A05190295.
Parvin, P., Zola, M., Dirani, A., Ambresin, A. & Mantel, I. (2017) Two‐year outcome of an observe‐and‐plan regimen for neovascular age‐related macular degeneration treated with aflibercept. Graefe's Archive for Clinical and Experimental Ophthalmology, 255, 2127–2134.
Rosenfeld, P.J., Brown, D.M., Heier, J.S., Boyer, D.S., Kaiser, P.K., Chung, C.Y. et al. (2006) Ranibizumab for neovascular age‐related macular degeneration. The New England Journal of Medicine, 355, 1419–1431.
Rozing, M.P., Durhuus, J.A., Krogh Nielsen, M., Subhi, Y., Kirkwood, T.B., Westendorp, R.G. et al. (2020) Age‐related macular degeneration: a two‐level model hypothesis. Progress in Retinal and Eye Research, 76, 100825.
Sedeh, F.B., Scott, D.A.R., Subhi, Y. & Sørensen, T.L. (2017) Prevalence of neovascular age‐related macular degeneration and geographic atrophy in Denmark. Danish Medical Journal, 64, A5422.
Sevik, M.O., Aykut, A., Özkan, G., Dericioğlu, V. & Şahin, Ö. (2021) The effect of COVID‐19 pandemic restrictions on neovascular AMD patients treated with treat‐and‐extend protocol. International Ophthalmology, 41, 2951–2961.
Subhi, Y., Henningsen, G.Ø., Larsen, C.T., Sørensen, M.S. & Sørensen, T.L. (2014) Foveal morphology affects self‐perceived visual function and treatment response in neovascular age‐related macular degeneration: a cohort study. PLoS One, 9, e91227.
Subhi, Y. & Sørensen, T.L. (2017) Neovascular age‐related macular degeneration in the very old (≥90 years): epidemiology, adherence to treatment, and comparison of efficacy. Journal of Ophthalmology, 2017, 7194927.
Thier, A., Breuning, M., Wolfram, C., Zeitz, O. & Holmberg, C. (2022) Emotional and physical experiences of people with neovascular age‐related macular degeneration during the injection process in Germany: a qualitative study. BMJ Open, 12, e058266.
van Dijk, E.H.C. & Boon, C.J.F. (2021) Serous business: delineating the broad spectrum of diseases with subretinal fluid in the macula. Progress in Retinal and Eye Research, 84, 100955.
Wong, T.Y., Chakravarthy, U., Klein, R., Mitchell, P., Zlateva, G., Buggage, R. et al. (2008) The natural history and prognosis of neovascular age‐related macular degeneration: a systematic review of the literature and meta‐analysis. Ophthalmology, 115, 116–126.
Wong, W.L., Su, X., Li, X., Cheung, C.M., Klein, R., Cheng, C.Y. et al. (2014) Global prevalence of age‐related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta‐analysis. The Lancet Global Health, 2, e106–e116.
Zarranz‐Ventura, J., Escobar‐Barranco, J.J., Gómez‐Baldó, L. & Gallego‐Pinazo, R. (2023) Reasons for delayed anti‐VEGF treatment during COVID‐19 lockdown and clinical impact in neovascular age‐related macular degeneration. Ophthalmology and therapy, 12, 2537–2555.